Telix Pharmaceuticals (ASX:TLX) said the Brazilian Health Regulatory Agency approved its prostate cancer imaging agent Illuccix, according to a Tuesday Australian bourse filing.
The marketing authorization was granted to Telix's partner R2PHARMA, a unit of Grupo GSH. Telix provided Grupo GSH with an exclusive license to manufacture, distribute, and market Illuccix in Brazil, the filing said.
Telix and R2PHARMA will set up a joint venture, Telix Innovations Brazil, to commercialize and distribute Telix's therapeutic and diagnostic radiopharmaceutical products in Brazil. Telix Innovations Brazil will hold the exclusive license to commercialize and distribute Illuccix as well as future product candidates.
Illuccix, after radiolabeling with gallium-68, is a radioactive diagnostic agent used in conjunction with positron emission tomography to detect prostate-specific membrane antigen-positive lesions in men with prostate cancer.
It is already commercially available in Australia, Canada, New Zealand, as well as the US, and has recently been approved in the UK.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.